Consistent with the role of immune checkpoints in self‐tolerance and autoimmunity, Khan et al [119] set out to apply PRS constructed for skin autoimmunity (psoriasis, vitiligo, atopic dermatitis) to a failed phase III clinical trial that tested the efficacy of the immune checkpoint inhibitor atezolizumab/anti‐PD‐L1 (CD274) as a bladder cancer treatment. This evidence concerns the gene CD274 and atopic eczema.